Bristol-Myers Squibb (NYSE:BMY) Shares Bought by Milestone Asset Management LLC

Milestone Asset Management LLC lifted its stake in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 102.2% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 54,006 shares of the biopharmaceutical company's stock after purchasing an additional 27,297 shares during the quarter. Milestone Asset Management LLC's holdings in Bristol-Myers Squibb were worth $3,294,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of BMY. Norges Bank purchased a new stake in Bristol-Myers Squibb in the 4th quarter worth about $1,989,525,000. Ameriprise Financial Inc. lifted its position in shares of Bristol-Myers Squibb by 59.9% during the 4th quarter. Ameriprise Financial Inc. now owns 32,079,246 shares of the biopharmaceutical company's stock worth $1,814,341,000 after buying an additional 12,011,983 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its position in shares of Bristol-Myers Squibb by 701.2% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,470,106 shares of the biopharmaceutical company's stock worth $705,309,000 after buying an additional 10,913,708 shares during the period. Wellington Management Group LLP lifted its position in shares of Bristol-Myers Squibb by 3,880.0% during the 4th quarter. Wellington Management Group LLP now owns 5,977,505 shares of the biopharmaceutical company's stock worth $338,088,000 after buying an additional 5,827,317 shares during the period. Finally, Raymond James Financial Inc. bought a new position in Bristol-Myers Squibb in the 4th quarter valued at $257,618,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Bristol-Myers Squibb Stock Up 0.2%

Shares of BMY stock traded up $0.09 during midday trading on Thursday, reaching $48.04. 5,715,573 shares of the stock were exchanged, compared to its average volume of 13,034,994. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. The company's 50 day moving average is $49.82 and its two-hundred day moving average is $55.19. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $63.33. The firm has a market cap of $97.77 billion, a PE ratio of -10.87, a price-to-earnings-growth ratio of 2.07 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The firm had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. During the same period in the prior year, the business posted ($4.40) EPS. Bristol-Myers Squibb's revenue was down 5.6% on a year-over-year basis. On average, equities research analysts predict that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Insider Buying and Selling at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 4,250 shares of the stock in a transaction that occurred on Friday, April 25th. The stock was purchased at an average price of $47.58 per share, with a total value of $202,215.00. Following the acquisition, the executive vice president now owns 83,513 shares in the company, valued at approximately $3,973,548.54. The trade was a 5.36% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.09% of the company's stock.

Analysts Set New Price Targets

BMY has been the topic of several analyst reports. William Blair reissued a "market perform" rating on shares of Bristol-Myers Squibb in a research note on Friday, April 25th. Cantor Fitzgerald restated a "neutral" rating and issued a $55.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. Wells Fargo & Company increased their price target on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a report on Friday, February 7th. Piper Sandler assumed coverage on Bristol-Myers Squibb in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price target for the company. Finally, UBS Group lowered their price target on Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a report on Friday, April 11th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have given a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, Bristol-Myers Squibb presently has an average rating of "Hold" and an average price target of $58.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.